TPD52L1在胃癌中的表达及其临床意义
Expression of TPD52L1 in Gastric Cancer and Its Clinical Significance
DOI: 10.12677/ACM.2023.1351039, PDF,   
作者: 汤小杰：青岛大学医学部，山东 青岛；曲海霞*：康复大学青岛医院(青岛市市立医院)消化内科，山东 青岛
关键词: TPD52L1；胃癌；临床病例特征；TPD52L1； Gastric Cancer； Clinical Case Characteristics
摘要: 目的：探究肿瘤蛋白家族D52 (TPD52)的成员TPD52L1 (TPD53)蛋白在胃癌及胃癌细胞中的表达，并分析其表达与胃癌患者临床病理特征的相关性。方法：收集2020年01月至2022年06月期间青岛市市立医院普外科经手术完整切除的胃癌及癌旁(距肿瘤组织5 cm以上，病理证实无癌组织浸润)标本总共33例。采用免疫组织化学法检测TPD52L1在33例胃癌组织中的表达，分析TPD52L1表达水平与胃癌病例特征的相关性。通过RT-qPCR检测TPD52L1在胃癌细胞系及人胃粘膜上皮细胞系中的表达水平。结果：在胃癌组织中TPD52L1的蛋白表达水平明显高于癌旁组织。此外，在胃癌细胞中，TPD52L1的蛋白表达水平同样高于正常人胃粘膜上皮细胞。结论：TPD52L1在胃癌组织中的表达水平明显高于癌旁组织，其表达水平与胃癌患者的性别、淋巴结转移情况有关。此外，在胃癌细胞中，TPD52L1的表达同样高于正常人胃粘膜上皮细胞。
Abstract: Objective: To investigate the expression of TPD52L1 (TPD53) protein, a member of the tumor pro-tein family D52 (TPD52), in gastric cancer and gastric cancer cells, and to analyze the correlation between its expression and clinicopathological characteristics in patients with gastric cancer. Methods: From January 2020 to June 2022, a total of 33 specimens of gastric cancer and its adjacent tissues (more than 5 cm away from the tumor tissue, pathologically confirmed without invasion of cancer tissue) were collected from the General Surgery Department of Qingdao Municipal Hospital. Immunohistochemical method was used to detect the expression of TPD52L1 in 33 cases of gastric cancer, and the correlation between the expression level of TPD52L1 and the characteristics of gas-tric cancer cases was analyzed. The expression level of TPD52L1 in gastric cancer cell lines and hu-man gastric mucosal epithelial cell lines was detected by RT-qPCR. Results: The protein expression level of TPD52L1 in gastric cancer tissue was significantly higher than that in adjacent tissues. In addition, the protein expression level of TPD52L1 in gastric cancer cells is also higher than that in normal human gastric mucosal epithelial cells. Conclusion: The expression level of TPD52L1 in gas-tric cancer tissue is significantly higher than that in adjacent tissues, and its expression level is re-lated to the gender and lymph node metastasis of gastric cancer patients. In addition, the expres-sion of TPD52L1 in gastric cancer cells is also higher than that in normal human gastric mucosal ep-ithelial cells.
文章引用：汤小杰, 曲海霞. TPD52L1在胃癌中的表达及其临床意义[J]. 临床医学进展, 2023, 13(5): 7447-7453. https://doi.org/10.12677/ACM.2023.1351039

参考文献

[1] Sung, H., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[2] GBD 2019 Diseases and Injuries Collaborators (2020) Global Burden of 369 Diseases and Injuries in 204 Countries and Territories, 1990-2019: A Systematic Analysis for the Global Burden of Disease Study 2019. The Lancet, 396, 1204-1222. [Google Scholar] [CrossRef] 
[3] Rawla, P. and Barsouk, A. (2019) Epidemiology of Gastric Cancer: Global Trends, Risk Factors and Prevention. Przegla̜d Gastro-enterologiczny, 14, 26-38. [Google Scholar] [CrossRef] [PubMed]
[4] Chemnitz, J.M., et al. (2004) SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation. The Journal of Immunology, 173, 945-954. [Google Scholar] [CrossRef] [PubMed]
[5] Aggen, D.H. and Drake, C.G. (2017) Biomarkers for Immuno-therapy in Bladder Cancer: A Moving Target. The Journal for ImmunoTherapy of Cancer, 5, 94. [Google Scholar] [CrossRef] [PubMed]
[6] Rosenberg, J.E., et al. (2016) Atezolizumab in Patients with Lo-cally Advanced and Metastatic Urothelial Carcinoma Who Have Progressed Following Treatment with Platinum-Based Chemotherapy: A Single-Arm, Multicentre, Phase 2 Trial. The Lancet, 387, 1909-1920. [Google Scholar] [CrossRef] 
[7] 戴维, 等. TPD52L1(D53)蛋白在膀胱尿路上皮癌中的表达和预后[J]. 安徽医科大学学报, 2019, 54(4): 635-639.
[8] 李雨濛, 任中海, 张敬伟, 胃癌患者血清白细胞介素-6及C-反应蛋白和血管内皮生长因子的表达及临床意义[J]. 医药论坛杂志, 2022, 43(5): 68-70+74.
[9] 程时磊, 张发斌, 李斌. 中国人群胃癌发病影响因素meta分析[J]. 中国公共卫生, 2017, 33(12): 1775-1780.
[10] 李健, 等. 胃癌影响因素研究进展[J]. 实用肿瘤学杂志, 2020, 34(5): 466-470.
[11] 王晓玲. 辅助化疗治疗胃癌的疗效评价和影响胃癌预后的多因素分析[J]. 现代消化及介入诊疗, 2016, 21(2): 319-321.
[12] Byrne, J.A., et al. (2014) Tu-mor Protein D52 (TPD52) and Cancer-Oncogene Understudy or Understudied Oncogene? Tumor Biology, 35, 7369-7382. [Google Scholar] [CrossRef] [PubMed]
[13] Byrne, J.A., et al. (1998) Identification of Homo- and Heteromeric Interactions between Members of the Breast Carcinoma-Associated D52 Protein Family Using the Yeast Two-Hybrid System. Oncogene, 16, 873-881. [Google Scholar] [CrossRef] [PubMed]
[14] Ross, D.T., et al. (2000) Systematic Variation in Gene Expression Patterns in Human Cancer Cell Lines. Nature Genetics, 24, 227-235. [Google Scholar] [CrossRef] [PubMed]
[15] Boutros, R. and Byrne, J.A. (2005) D53 (TPD52L1) Is a Cell Cycle-Regulated Protein Maximally Expressed at the G2-M Transition in Breast Cancer Cells. Experimental Cell Research, 310, 152-165. [Google Scholar] [CrossRef] [PubMed]

为你推荐